Business Wire
06 Dec 2025, 19:00 UTC · 46w ago
Verdict
Headline takes no side. We score ARCX +0.80 — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Announced positive data showing deep and durable efficacy for its investigational agent in RRMM patients.
More positive than 87% of ticker scores this week
Positive clinical data from a pivotal Phase 2 study for a multiple myeloma treatment developed by its subsidiary.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 74% of relationship scores this week
[mutual] Gilead's subsidiary Kite and Arcellx are partners in the iMMagine-1 Phase 2 study for anito-cel.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
19h ago
−86.2%
Price is moving against the score
$6.67 vs $48.34 close before publication (Dec 5) · not market-adjusted
ARCX chart →
